Diagnostic antibodies and antigens for Neurodegenerative diseases testing: Phospho-tau181 (p-tau181), Phospho-tau217 (p-tau217), tau proteins (Tau), neurofilament light chain (NFL), neurofilament protein (AD7c-NTP)

Neurodegenerative diseases refer to the injury or dysfunction of one or more nerves, which results in numbness, tingling, muscle weakness and discomfort in the nerves affected part. Alzheimer’s disease (AD) is a progressive neurodegenerative disease most often characterized by initial memory impairment and cognitive decline that can ultimately affect behavior, speech, visuospatial orientation and the motor system, and it is the most common form of dementia. Peripheral neuropathy refers the injury or dysfunction of the peripheral nerves. Peripheral neuropathy might be acute or chronic, and sometimes it is reversible. Biochemical markers are increasingly used for the early diagnosis of the neuropathy. In addition, such markers may provide additional information for understanding the pathology of disease. Several markers such as a Phospho-tau181 (p-tau181), Phospho-tau217 (p-tau217), Phospho-tau231 (p-tau231), tau proteins (Tau), neurofilament light chain (NFL), Glial fibrillary acid protein (GFAP), beta-amyloid 42 (Aβ42), beta-amyloid 40 (Aβ40), AD-associated neuaronal thread protein (AD7c-NTP) and so on have been identified to be associated with the neurodegenerative diseases. Evidence has shown plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL and Aβ42/40) were significantly changed in preclinical Alzheimer Disease (AD). Detecting the quantity of these marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.

Evidence has shown plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL, and Aβ42/40) were significantly changed in preclinical Alzheimer’s Disease (AD). Recently, our R&D department demonstrated that our GMP-h-p-tau217-Ab01 has a large linear range and good sensitivity against the GMP-h-p-tau217-Ag01. Below is the result of GeneMedi’s GMP-h-p-tau217-Ab01 (Anti-human p-tau217 antibody) validation with GMP-h-p-tau217-Ag01 (p-tau217 antigen) in ELISA. We highly recommend the Ab&Ag to you.